相关实验视频
Updated: Jun 14, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
生物类似药与青少年无形性关节炎儿童的原始药:现实世界的经验
概括
与原始药物相比,Etanercept和Adalimumab生物仿制药在患有青少年异常性关节炎的儿童中显示出更好的疗效和更低的免疫性. 需要进一步的研究来证实这些发现,在青少年异常性关节炎患者.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 儿科 儿科 儿科
背景情况:
- 青少年异常性关节炎 (JIA) 是一种慢性自身免疫性疾病,影响儿童.
- 乙素 (ETA) 和阿达利穆马布 (ADA) 是用于治疗JIA的生物疗法.
- 生物类似药 (BIO) 为原始生物制品提供了潜在的替代品.
研究的目的:
- 为了比较ETA和ADA生物类似药的疗效,安全性和免疫性,与其原始药在儿科JIA患者中进行比较.
- 评估疾病活动,抗药抗体水平和复发率.
主要方法:
- 一项涉及81名患有JIA的儿童接受ETA或ADA原始物或生物类似物治疗的研究.
- 在基线和治疗开始后的3,6,12,24个月收集的数据.
- 青少年关节炎疾病活动评分10 (JADAS-10),抗药抗体,复发率和安全概况的评估.
主要成果:
- 生物相似治疗组在所有时间点 (p <0.05) 显示与原始治疗组相比,JADAS-10得分明显较低.
- 在3个月和12个月接受生物类似药的儿童中观察到较低的抗药抗体水平 (分别为p = 0.04和p = 0.0007).
- 生物类似药与复发的显著减少有关 (p < 0.001) 具有相似的安全性.
结论:
- 与原始药物相比,Etanercept和Adalimumab生物类似药在患有JIA的儿童中表现出优越的整体特征.
- 这些发现表明,生物类似药可能是儿童JIA更有效的治疗选择.
- 建议进行更大规模的证实性研究来验证这些有希望的结果.
相关概念视频
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Prescription, Nonprescription and Orphan Drugs
706
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
706
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120

